Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
ConclusionThe heterogeneous spectrum of post-marketing toxicities for ADCs used in breast cancer, as emerging from the FAERS, is largely in line with preapproval evidence. Although causality cannot be proved, we call for increased awareness by oncologists on potential serious unexpected reactions, including early onset of septic shock and neutropenic colitis with SG, and late emergence of pulmonary embolism with T-DM1. (Source: Targeted Oncology)
Source: Targeted Oncology - May 2, 2024 Category: Cancer & Oncology Source Type: research
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
ConclusionIn line with the results of the TOPAZ-1 trial, adding durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of OS and PFS in a real-world setting of patients with advanced BTC. (Source: Targeted Oncology)
Source: Targeted Oncology - May 1, 2024 Category: Cancer & Oncology Source Type: research
Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study
ConclusionsThis is the first administrative data-based real-world evidence on treatment sequence and outcomes for patients with early recurrence CRC treated with FOLFIRI+AAs or FOLFIRI+ anti-EGFR antibodies after adjuvant FOLFOX/CAPOX therapy in Japan. Both regimens had similar TTD, but relapse timing and tumor sidedness may influence their efficacy. (Source: Targeted Oncology)
Source: Targeted Oncology - May 1, 2024 Category: Cancer & Oncology Source Type: research
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer
ConclusionsEnvafolimab yielded promising surgical outcomes and safety in dMMR/MSI-H locally advanced colon cancer, representing a promising treatment modality for this population. (Source: Targeted Oncology)
Source: Targeted Oncology - April 30, 2024 Category: Cancer & Oncology Source Type: research
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
ConclusionsAs demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab. (Source: Targeted Oncology)
Source: Targeted Oncology - April 30, 2024 Category: Cancer & Oncology Source Type: research
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
ConclusionsThrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD.The study was registered with ClinicalTrials.gov (NCT03106428). (Source: Targeted Oncology)
Source: Targeted Oncology - April 29, 2024 Category: Cancer & Oncology Source Type: research
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes
ConclusionsIn the MCD subtype, patients withMYD88-CD79Bco-mut showed comparable PFS and OS compared toMYD88/CD79Bsingle-mut orMYD88-CD79Bco-wt, while in the non-MCD subtype, they exhibited significantly inferior OS. There was no significant disparity in PFS and OS ofMYD88-CD79Bco-mut between the MCD and non-MCD subtypes. The presence ofPIM1mut within theMYD88-CD79Bco-mut group correlated with better PFS, which may result from an intricate interplay of immune processes and tumor microenvironment alterations. (Source: Targeted Oncology)
Source: Targeted Oncology - April 21, 2024 Category: Cancer & Oncology Source Type: research
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
ConclusionsFor patients with multiple myeloma, treatment with RUX and MP is effective and well tolerated, and LEN can be used to extend the benefit of this RUX-based treatment.Clinical Trial RegistrationThis study is registered with ClinicalTrials.gov, NCT03110822, and is ongoing. (Source: Targeted Oncology)
Source: Targeted Oncology - April 20, 2024 Category: Cancer & Oncology Source Type: research
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
ConclusionsOur data demonstrate thatRAS mutations do not affect outcome in rego-treated patients as well as TFD/TPI-treated patients. Nevertheless, a trend toward a higher efficacy of rego inRAS-mutated (in particular codon 12, rareRAS mutations, and G12D) patients has been recorded. The rego-TFD/TPI sequence seems to be superior to the reverse sequence in patients carrying anRAS codon 12 mutation, although the impact of other factors as disease burden or performance status cannot be excluded. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2024 Category: Cancer & Oncology Source Type: research
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
ConclusionsOsimertinib rechallenge after initial pneumonitis was associated with significantly higher recurrence rates than conventional EGFR-TKI rechallenge. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2024 Category: Cancer & Oncology Source Type: research
The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling
ConclusionsReal-world datasets from clinical panel testing revealed the genomic landscape in gastric cancer by subgroup. These findings provide insights for the current therapeutic strategies and future development of treatments in gastric cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2024 Category: Cancer & Oncology Source Type: research
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer
ConclusionsWe noted important differences in co-occurring GA inERBB2-altered (ECDmut+, KDmut+, amp+) versusERBB2wt UBC, as well as higher mean TMB and higher APOBEC mutational signature in theERBB2-altered groups. Our results can help refine future clinical trial designs and elucidate possible response and resistance mechanisms forERBB2-altered UBC. (Source: Targeted Oncology)
Source: Targeted Oncology - April 3, 2024 Category: Cancer & Oncology Source Type: research
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor
ConclusionsEGFR-Erbitux receptor targeted EnGeneIC Dream Vector with mitoxantrone can be safely delivered in paediatric patients aged 2 –21 years with solid or CNS tumours harbouring EGFR expression. The discovery of EGFR expression in a high proportion of paediatric gliomas means that EGFR may be useful as a target for other treatment strategies. Targeted therapeutic-loaded EDVs may be worth exploring further for their role in st imulating an anti-tumour immune response.ClinicalTrials.gov IdentifierNCT02687386. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
ConclusionsIn this systematic review, data from RCTs showed that palbociclib was effective, well tolerated, and maintained QoL in older patients with HR+/HER2 − a/mBC. Palbociclib treatment in older patients in real-world settings was associated with similar clinical benefit as in RCTs.PROSPERO RegistrationCRD42023444195. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
ConclusionsA superior effect of EV on patient survival compared to re-challenging chemotherapy and continuing pembrolizumab beyond PD was observed in our real-world analysis, which is attributed to the durable DOR in EV treatment despite the similar ORR to re-challenging chemotherapy. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
